Erasca, Inc.
ERASDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Aug 11, 2026
4wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
How ERAS's past catalysts played out
Naporafenib
Advanced or Metastatic NRAS-mutant Melanoma
Encorafenib
Metastatic Colorectal Cancer
ERAS-007
Advanced or Metastatic Solid Tumors
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Naporafenib | Phase 3 | Advanced or Metastatic NRAS-mutant Melanoma | - | - |
Encorafenib | Phase 2 | Metastatic Colorectal Cancer | - | - |
ERAS-007 | Phase 2 | Advanced or Metastatic Solid Tumors | - | - |
Advanced or Metastatic NRAS-mutant Melanoma
1 drug in this indication
Metastatic Colorectal Cancer
1 drug in this indication
Advanced or Metastatic Solid Tumors
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Erasca, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Erasca, Inc.'s (ERAS) pipeline across Phase 3, Phase 2. Its lead program is Naporafenib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Erasca, Inc.'s next FDA catalyst?→
Erasca, Inc.'s (ERAS) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ERAS biotech catalysts?→
Add ERAS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Erasca, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.